-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Castle Biosciences Expects Preliminary 2025 Revenue To Exceed $340M, Beating Prior $327M-$335M Guide; Year-End Cash And Marketable Securities ~ $300M

Benzinga·01/12/2026 07:27:08
Listen to the news
  • 2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million
  • 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024
  • Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million